keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis c" cost

keyword
https://www.readbyqxmd.com/read/27920481/new-real-time-pcr-method-to-identify-single-point-mutations-in-hepatitis-c-virus
#1
Qian Chen, Irene Belmonte, Maria Buti, Leonardo Nieto, Damir Garcia-Cehic, Josep Gregori, Celia Perales, Laura Ordeig, Meritxell Llorens, Maria Eugenia Soria, Rafael Esteban, Juan Ignacio Esteban, Francisco Rodriguez-Frias, Josep Quer
AIM: To develop a fast, low-cost diagnostic strategy to identify single point mutations in highly variable genomes such as hepatitis C virus (HCV). METHODS: In patients with HCV infection, resistance-associated amino acid substitutions within the viral quasispecies prior to therapy can confer decreased susceptibility to direct-acting antiviral agents and lead to treatment failure and virological relapse. One such naturally occurring mutation is the Q80K substitution in the HCV-NS3 protease gene, which confers resistance to PI inhibitors, particularly simeprevir...
November 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27917405/efficacy-and-safety-of-3-week-response-guided-triple-direct-acting-antiviral-therapy-for-chronic-hepatitis-c-infection-a-phase-2-open-label-proof-of-concept-study
#2
George Lau, Yves Benhamou, Guofeng Chen, Jin Li, Qing Shao, Dong Ji, Fan Li, Bing Li, Jialiang Liu, Jinlin Hou, Jian Sun, Cheng Wang, Jing Chen, Vanessa Wu, April Wong, Chris L P Wong, Stella T Y Tsang, Yudong Wang, Leda Bassit, Sijia Tao, Yong Jiang, Hui-Mien Hsiao, Ruian Ke, Alan S Perelson, Raymond F Schinazi
BACKGROUND: To shorten the course of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, we examined the antiviral efficacy and safety of 3 weeks of response-guided therapy with an NS3 protease inhibitor and dual NS5A inhibitor-NS5B nucleotide analogue. METHODS: In this open-label, phase 2a, single centre study, Chinese patients with chronic HCV genotype 1b infection without cirrhosis were randomly allocated by a computer program to one of three treatment groups (sofosbuvir, ledipasvir, and asunaprevir; sofosbuvir, daclatasvir, and simeprevir; or sofosbuvir, daclatasvir, and asunaprevir) until six patients in each group (1:1:1) achieved an ultrarapid virological response (plasma HCV RNA <500 IU/mL by day 2, measured by COBAS TaqMan HCV test, version 2...
October 2016: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27916433/assessment-of-cost-sharing-in-the-pima-county-marketplace
#3
Nicholas B Jennings, Howard J Eng
The Patient Protection and Affordable Care Act established health insurance marketplaces to allow consumers to make educated decisions about their health care coverage. During the first open enrollment period in 2013, the federally facilitated marketplace in Pima County, Arizona listed 119 plans, making it one of the most competitive markets in the country. This study compares these plans based on differences in consumer cost sharing, including deductibles, co-pays and premiums. Consumer costs were reviewed using specific cases including a normal delivery pregnancy, the management of Type II Diabetes, and the utilization of specialty drugs to treat Hepatitis C...
November 8, 2016: Health Policy
https://www.readbyqxmd.com/read/27904646/hepatitis-c-among-healthcare-personnel-secondary-data-analyses-of-costs-and-trends-for-hepatitis-c-infections-with-occupational-causes
#4
Claudia Westermann, Madeleine Dulon, Dana Wendeler, Albert Nienhaus
BACKGROUND: Hepatitis C infection is a global public health issue. Chronic hepatitis C infection is associated with significant morbidity and mortality. The aim of this study is to describe the costs for occupationally-cased hepatitis C infections based on data from an accident insurance carrier. METHODS: This study is a secondary analysis based on the Database of a German Institution for Statutory Accident Insurance. The analysis is based on a sample of insured parties whose hepatitis C infections were recorded as occupational diseases between 1996 and 2013...
2016: Journal of Occupational Medicine and Toxicology
https://www.readbyqxmd.com/read/27893348/cost-utility-and-budget-impact-of-methylene-blue-treated-plasma-compared-to-quarantine-plasma
#5
Joseph B Babigumira, Solomon J Lubinga, Emma Castro, Brian Custer
BACKGROUND: Methylene blue and visible light treatment and quarantine are two methods used to reduce adverse events, mostly infections, associated with the transfusion of fresh-frozen plasma. The objective of this study was to estimate and compare the budget impact and cost-utility of these two methods from a payer's perspective. MATERIALS AND METHODS: A budget impact and cost-utility model simulating the risks of hepatitis B virus, hepatitis C virus, cytomegalovirus, a West Nile virus-like infection, allergic reactions and febrile non-haemolytic transfusion reactions achieved using plasma treated with methylene blue and visible light (MBP) and quarantine plasma (QP) was constructed for Spain...
November 16, 2016: Blood Transfusion, Trasfusione del Sangue
https://www.readbyqxmd.com/read/27882839/real-world-drug-costs-of-treating-hepatitis-c-genotypes-1-4-with-direct-acting-antivirals-initiating-treatment-at-fibrosis-0-2-and-3-4
#6
Timothy A Bach, Kathy Zaiken
BACKGROUND: Direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) have drastically improved outcomes but are also very costly. For this reason, priority for treatment is often given to patients with a higher fibrosis score at baseline by payers and providers rather than treating all eligible patients. Simulation studies have suggested that waiting to treat patients until fibrosis 3-4 may be more costly and result in worse outcomes; however, real-world implications are unknown...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27871760/hepatitis-c-treatment-clinical-issues-for-psychiatrists-in-the-post-interferon-era
#7
REVIEW
Yvonne Chasser, Arthur Y Kim, Oliver Freudenreich
BACKGROUND: Hepatitis C virus (HCV) is a widespread and costly cause of morbidity and mortality globally and in the United States. The treatment of HCV has been revolutionized with the recent development of direct-acting antiviral medications. These new treatments are substantially better tolerated and more efficacious than previously used interferon-based therapies. Despite these innovations, sustained virologic response has remained low, hovering at approximately 9% of all infected persons...
September 14, 2016: Psychosomatics
https://www.readbyqxmd.com/read/27859444/spending-on-hepatitis-c-antivirals-in-the-united-states-2009-2015
#8
Katie J Suda, Drew J Halbur, Robert J Hunkler, Linda M Matusiak, Glen T Schumock
STUDY OBJECTIVE: New hepatitis C virus (HCV) antivirals have been shown to be highly effective with minimal adverse effects, but they are costly. Little is known, however, about the impact of the new HCV antivirals on expenditures to the overall U.S. health care system or by health care sector. Thus, the objective of this study was to describe HCV antiviral expenditures by agent, year, and health care sector. DESIGN: Retrospective, cross-sectional study. DATA SOURCE: QuintilesIMS National Sales Perspectives database...
November 9, 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27845789/simultaneous-detection-of-multiple-viruses-based-on-chemiluminescence-and-magnetic-separation
#9
Zeeshan Ali, Jiuhai Wang, Yongjun Tang, Bin Liu, Nongyue He, Zhiyang Li
Nucleic acid testing (NAT) based methods are more sensitive and specific, and are preferred over enzyme immunoassays. Different NAT based protocols have been designed to detect multiple pathogens in order to reduce the inherent high cost for detection. However, these assays do not reliably detect a large number of pathogens at once. In this report, a DNA hybridization based chemiluminescence detection method has been proposed for reliable detection of multiple pathogens. The idea was practically demonstrated by carrying out simultaneous extraction and amplification of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV-1 group M, herein referred to as HIV) through the one step multiplex reverse transcription polymerase chain reaction (RT-PCR)...
November 15, 2016: Biomaterials Science
https://www.readbyqxmd.com/read/27836599/gold-aggregating-gold-a-novel-nanoparticle-biosensor-approach-for-the-direct-quantification-of-hepatitis-c-virus-rna-in-clinical-samples
#10
Sherif M Shawky, Ahmed M Awad, Walaa Allam, Mohamed H Alkordi, Sherif F El-Khamisy
The affordable and reliable detection of Hepatitis C Virus (HCV) RNA is a cornerstone in the management and control of infection, affecting approximately 3% of the global population. However, the existing technologies are expensive, labor intensive and time consuming, posing significant limitations to their wide-scale exploitation, particularly in economically deprived populations. Here, we utilized the unique optical and physicochemical properties of gold nanoparticles (AuNPs) to develop a novel assay platform shown to be rapid and robust in sensing and quantifying unamplified HCV RNA in clinical samples...
November 4, 2016: Biosensors & Bioelectronics
https://www.readbyqxmd.com/read/27832039/a-clinician-s-guide-to-the-cost-and-health-benefits-of-hepatitis-c-cure-assessed-from-the-individual-patient-perspective
#11
Phil McEwan, Nowlan Selvapatt, Ashley Brown, Mark Thursz, Hayley Bennett, Samantha Webster, Anupama Kalsekar, Yong Yuan, Michael Brenner, Jason Gordon
BACKGROUND AND AIMS: The hepatitis C virus (HCV) remains a considerable public health challenge. Novel direct-acting antiviral (DAA) regimens offer high cure rates and the promise of reduced HCV incidence and prevalence following the up-scaling of treatment. This has focused attention towards affordability. This study aimed to estimate the economic value of cure to evaluate the treatment costs justifiable from the patient perspective. PATIENTS AND METHODS: A published, validated HCV model was utilized to contrast clinical and cost outcomes for patients aged 30-70 years, stratified by METAVIR F0-F4, for (i) no treatment and (ii) successful treatment [i...
November 9, 2016: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27818057/using-silver-nanoparticle-and-thiol-graphene-quantum-dots-nanocomposite-as-a-substratum-to-load-antibody-for-detection-of-hepatitis-c-virus-core-antigen-electrochemical-oxidation-of-riboflavin-was-used-as-redox-probe
#12
Akram Valipour, Mahmoud Roushani
In this study a facile green approach to employ silver nanoparticle (AgNPs) and thiol graphene quantum dots (GQD-SH) as the nanomaterial for ultrasensitive and selective detection of hepatitis C virus core antigen (HCV) have been investigated. AgNPs/GQD-SH was utilized as a substratum to load antibody for detection of hepatitis C virus core antigen. AgNPs have been immobilized on SH groups of GQDs via bonding formation of Ag-S and anti-HCV have been loaded on the electrode surface via the interaction between -NH2 group of antibody and AgNPs...
September 28, 2016: Biosensors & Bioelectronics
https://www.readbyqxmd.com/read/27807238/clinically-approved-ion-channel-inhibitors-close-gates-for-hepatitis-c-virus-and-open-doors-for-drug-repurposing-in-viral-infectious-diseases
#13
Thomas Pietschmann
Chronic hepatitis C virus (HCV) infection causes severe liver disease and affects ca. 146 million individuals. Novel directly acting antivirals targeting HCV have revolutionized treatment. However, high costs limits access to therapy. Recently, several related drugs used in humans to treat allergies or as neuroleptics emerged as potent HCV cell entry inhibitors. Insights into their antiviral mode of action may access opportunities for drug repurposing in hepatitis C and possibly other important human viral infections...
November 2, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27806712/the-brazilian-comprehensive-response-to-hepatitis-c-from-strategic-thinking-to-access-to-interferon-free-therapy
#14
Fabio Mesquita, Melina Erica Santos, Adele Benzaken, Renato Girade Corrêa, Elisa Cattapan, Leandro Soares Sereno, Marcelo Contardo Moscoso Naveira
BACKGROUND: Hepatitis C affects over 185 million people around the world. This silent disease is responsible for up to 700,000 deaths per year. Despite the scientific revolution in diagnosis and treatment, hepatitis C control remains a huge challenge due to the cost of effective medications. In response to the global outcry of hepatitis epidemic and the need to improve the nation's public health response, the Ministry of Health of Brazil revolutionized hepatitis C treatment by incorporating highly effective drugs that can be accessed through sustainable and universal means...
November 2, 2016: BMC Public Health
https://www.readbyqxmd.com/read/27804195/the-value-of-cure-associated-with-treating-treatment-na%C3%A3-ve-chronic-hepatitis-c-genotype-1-are-the-new-all-oral-regimens-good-value-to-society
#15
Zobair M Younossi, Haesuk Park, Douglas Dieterich, Sammy Saab, Aijaz Ahmed, Stuart C Gordon
BACKGROUND & AIMS: All-oral regimens are associated with high cure rates in hepatitis C virus-genotype 1 (HCV-GT1) patients. Our aim was to assess the value of cure to the society for treating HCV infection. METHODS: Markov model for HCV-GT1 projected long-term health outcomes, life years, and quality-adjusted life years (QALYs) gained. The model compared second-generation triple (sofosbuvir+pegylated interferon+ribavirin [PR] and simeprevir+PR) and all-oral (ledipasvir/sofosbuvir and ombitasvir+paritaprevir/ritonavir+dasabuvir±ribavirin) therapies with no treatment...
November 2, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27803989/hepatitis-c-disease-transmission-and-treatment-uptake-impact-on-the-cost-effectiveness-of-new-direct-acting-antiviral-therapies
#16
Hayley Bennett, Jason Gordon, Beverley Jones, Thomas Ward, Samantha Webster, Anupama Kalsekar, Yong Yuan, Michael Brenner, Phil McEwan
BACKGROUND: Hepatitis C virus (HCV) treatment can reduce the incidence of future infections through removing opportunities for onward transmission. This benefit is not captured in conventional cost-effectiveness evaluations of treatment and is particularly relevant in patient groups with a high risk of transmission, such as those people who inject drugs (PWID), where the treatment rates have been historically low. This study aimed to quantify how reduced HCV transmission changes the cost-effectiveness of new direct-acting antiviral (DAA) regimens as a function of treatment uptake rates...
November 1, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/27799299/arabinoxylan-rice-bran-biobran-suppresses-the-viremia-level-in-patients-with-chronic-hcv-infection-a-randomized-trial
#17
Hosny Salama, Eman Medhat, Magda Shaheen, Abdel-Rahman N Zekri, Tarneem Darwish, Mamdooh Ghoneum
Current treatments for Hepatitis C virus (HCV) have severe side effects and are very expensive. There is a need to explore effective natural therapies against HCV that are less toxic and more cost-effective. In the current study, 37 chronic HCV patients were randomized into two groups and treated with either pegylated interferon (PEG IFN) plus ribavirin (n = 21) or Biobran, an arabinoxylan from rice bran (1 g/day) (n = 16). We examined viremia, liver enzymes, interferon-γ (IFN-γ) levels in serum, and toxicity before and three months after treatment...
October 31, 2016: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/27789966/disease-progression-and-health-care-resource-consumption-in-patients-affected-by-hepatitis-c-virus-in-real-practice-setting
#18
Valentina Perrone, Diego Sangiorgi, Stefano Buda, Luca Degli Esposti
INTRODUCTION: Hepatitis C virus (HCV) infection represents serious health problems worldwide and is a major contributor to end-stage liver disease including cirrhosis and hepatocellular carcinoma (HCC). In Italy, ~2% of subjects are infected with HCV. The objective of this study was to describe treatment patterns, disease progression, and resource use in HCV. METHODS: An observational retrospective cohort analysis based on four Local Health Units administrative and laboratory databases was conducted...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27785310/hepatitis-c-in-liver-allograft-recipients-utility-of-one-year-post-transplantation-biopsy-as-an-indicator-of-antiviral-therapy
#19
Shahid Habib, Shahid Malik, Bo Fu, Joyce Chang, Michael Nalesnik, Abhinav Humar, Obaid S Shaikh
BACKGROUND: All-oral interferon-free regimens for hepatitis C viral (HCV) infection are highly efficacious; however, high cost is a barrier to applicability. Liver allograft recipients are particularly likely to benefit from therapy as HCV often leads to graft dysfunction and loss. In this study, we aimed to establish the utility of allograft biopsy at 1 year post-transplant as an indicator of treatment. METHODS AND RESULTS: Among 252 liver recipients enrolled, 136 (54%) developed severe disease (fibrosing cholestatic hepatitis (FCH) or fibrosis stage ≥ 2 at 1 year post-transplant)...
December 2015: Gastroenterology Research
https://www.readbyqxmd.com/read/27783223/value-of-treating-all-stages-of-chronic-hepatitis-c-a-comprehensive-review-of-clinical-and-economic-evidence
#20
REVIEW
Roberto Nuño Solinís, Patricia Arratibel Ugarte, Ander Rojo, Yuri Sanchez Gonzalez
INTRODUCTION: The goal of chronic hepatitis C (CHC) treatment is to achieve a sustained virologic response (SVR). The new generation of direct-acting antivirals (DAAs) offers 90-100% SVR rates. However, access to these treatments is generally limited to patients with advanced liver disease. The aim of this review is to provide an overview of the clinical and economic benefits of achieving SVR and to better understand the full value of CHC treatment in all stages of liver disease. METHODS: A comprehensive literature review was performed using the PubMed, Embase, and Cochrane library databases to identify articles examining the clinical, economic, and quality of life benefits associated with SVR...
October 25, 2016: Infectious Diseases and Therapy
keyword
keyword
90225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"